Moderate to severe vasomotor symptoms of menopause. Vulvar or vaginal atrophy. Postmenopausal osteoporosis prevention. Hypoestrogenism.
Apply 1 patch once weekly to lower abdomen or upper buttock (avoid breasts, waistline); rotate application sites. Hypoestrogenism: see literature. Other uses: initially one 0.025mg/day patch. Give cyclically (3 weeks on, 1 week off). Reevaluate periodically. Postmenopausal osteoporosis: supplement diet with calcium 1.5g/day.
Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Breast or estrogen-dependent carcinoma. Pregnancy (Cat.X).
Patients with intact uterus should almost always receive a progestin to avoid endometrial hyperplasia. Familial hyperlipoproteinemia or history of breast cancer. Hepatic insufficiency. Conditions aggravated by fluid retention. Endometriosis. Gallbladder disease. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include Pap smear, mammogram, and BP). Discontinue if hypertension or jaundice occurs and during immobilization, or at least 2 weeks before surgery associated with increased risk of thromboembolism. Nursing mothers.
See literature. Local irritation, fluid retention, breakthrough bleeding, mastodynia, nausea, abdominal cramps, headache, migraine, dizziness, intolerance to contact lenses.